NCR102
/ Nuwacell Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 25, 2025
A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
(clinicaltrials.gov)
- P1/2 | N=24 | Not yet recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd.
New P1/2 trial • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology
1 to 1
Of
1
Go to page
1